Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir®)

This short report is dedicated to the description of the wide antiviral and antibacterial activity of the immune-modulating agent Panavir®. Panavir® is a high-molecular-weight fraction of the polysaccharides extracted from the shoots of the Solanum tuberosum. It demonstrates activity against many ty...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biological macromolecules 2020-10, Vol.161, p.936-938
Main Authors: Kalinina, Tatiana S., Zlenko, Dmitry V., Kiselev, Aleksei V., Litvin, Alexander A., Stovbun, Sergey V.
Format: Article
Language:English
Subjects:
Adult
Animals
Antiviral activity
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Betacoronavirus - drug effects
Coronavirus Infections - drug therapy
Coronavirus Infections - virology
COVID-19
Disease Models, Animal
Dysentery, Bacillary - drug therapy
Female
Glycosides - chemistry
Glycosides - pharmacology
Glycosides - therapeutic use
Herpes Genitalis - drug therapy
Humans
Immune modulator
Klebsiella Infections - drug therapy
Klebsiella pneumoniae - drug effects
Male
Mice
Middle Aged
Pandemics
Pneumonia, Viral - drug therapy
Pneumonia, Viral - virology
SARS-CoV-2
Shigella flexneri - drug effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This short report is dedicated to the description of the wide antiviral and antibacterial activity of the immune-modulating agent Panavir®. Panavir® is a high-molecular-weight fraction of the polysaccharides extracted from the shoots of the Solanum tuberosum. It demonstrates activity against many types of viruses, including animal coronavirus and also against bacterial infections. These properties look very promising considering the COVID-19 epidemy and allow propose that Panavir® would be effective in the therapy of the SARS-CoV-2 infection.
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2020.06.031